Applicants claim priority under 35 U.S.C. §119 of German Application No. 10 2005 007 592.4 filed Feb. 18, 2005. Applicants also claim priority under 35 U.S.C. §365 of PCT/EP2006/050006 filed Jan. 3, 2006. The international application under PCT article 21(2) was not published in English.
The present invention relates to a device for determining at least one hemodynamic parameter of a living being, particularly a device for determining cardiopulmonary volumes and flows of a living being.
Devices for determining hemodynamic parameters from a dilution curve obtained by means of invasive measurements are in broad use, particularly in intensive-care medicine. In this connection, the hemodynamic parameters are, in particular, characteristic volumes or volume flows, such as the cardiac output (CO), the global end-diastolic volume (GEDV), and the volume of the extravasal lung water (EVLW). Corresponding systems are commercially available and usually work with cold (i.e. a cooled bolus) as the indicator. In addition to the right-heart catheter systems that are widespread, with which thermodilution measurements are carried out with the pulmonary artery as the measurement site, systems for transpulmonary thermodilution measurement have established themselves on the market.
Methods and devices for transpulmonary thermodilution measurement have been disclosed in WO 93/21823 A1 and WO 01/30237 A1, among others, as well as the literature cited in them.
In the determination of hemodynamic parameters on the basis of measured dilution curves, inaccuracies or errors can occur on the basis of patient-specific anomalies. Such anomalies include short-circuit disruption functions of the right atrium to the left atrium (so-called right-left shunt, RL shunt), or from the left ventricle to the right ventricle (so-called left-right shunt, LR shunt).
The determination of a left-right shunt within the framework of a thermodilution measurement with a right-heart catheter is disclosed in U.S. Pat. No. 5,595,181. In this connection, the shunt determination takes place by means of a comparison of the temperature progression over time with an assumed temperature progression without shunt. Since a temperature progression without shunt is necessarily unknown for the same individual under identical conditions, this is merely an estimate of rather low accuracy. The use of a right-heart catheter in the form of a conventional balloon catheter furthermore bears a not insignificant medical risk, since here, the heart itself is fundamentally the object of an invasive measure. Furthermore, the defect of a right-left shunt, which occurs significantly more frequently, is not taken into consideration.
In the dissertation by J. K. G. Wietach, “Die Doppelindikatordilution zur Quantifizierung von Herzzeitvolumen und Links-Rechts-Shunt bei Patienten mit kongenitalem Vitium cordis” [Dual-indicator dilution for quantification of cardiac output and left-right shunt in patients suffering from congenital vitium cordis], Göttingen 1995, the determination of a left-right shunt by means of the dual-indicator dilution technique is described, i.e. by means of parallel determination of dilution curves by means of pulmonary artery measurement and aorta measurement. Here, too, the application of a right-heart catheter is required for the pulmonary artery measurement, with the attendant medical risks.
With this background, it is the task of the invention to create a device for determining hemodynamic parameters of a living being, which guarantee reliable hemodynamic monitoring, which is as gentle on the patient as possible and subject to little error, even in the case of patients having heart defects that cause short-circuit currents.
This task is accomplished according to one aspect of the present invention, with a device disclosed herein.
Advantageous embodiments of the invention can be configured according to further embodiments disclosed herein.
In surprising manner, even for a person skilled in the art, a suitable program technology set-up of the evaluation unit of a transpulmonary measurement arrangement, preferably having a central-vein catheter and an arterial catheter, is sufficient to take a possible short-circuit current from the right to the left half of the heart (RL shunt) and/or from the left to the right half of the heart (LR shunt) into consideration, without the use of a right-heart catheter being required for this, or recourse to pulmonary artery measurement values having to take place at all.
In this connection, a model is preferably used as the basis, in which the function y that corresponds to the dilution curve is included as a convolution of the disruption function I with several terms that contain characteristic times as model parameters. The terms correspond to ideally mixed volumes or delay elements that are stated as simplifications for the right atrium RA, the right ventricle RV, the pulmonary blood volume PBV, the extravasal thermal volume ETV, the left atrium LA, and the left ventricle LV.
The shunt can be in both directions as well as intracardial and extracardial.
Preferably, the evaluation unit is set up, in terms of program technology, to carry out the following steps: (a) estimating a starting point and a dilution peak of the dilution curve y, (b) calculating a mean transit time MTT=∫y·t dt/∫y dt (with time variable t) and a decay time DST (from the exponential decay of the dilution curve y according to y∞exp(−t/DST) after the dilution peak, (c) determining model parameters of the underlying model, using the mean transit time MTT and the decay time DST, (e) calculating the cardiac output CO and a short-circuit current ratio s, (f) calculating the terms that contain the model parameters, and (g) calculating the hemodynamic parameter.
The determination of the model parameters can advantageously take place by means of the partial steps (i) adapting a model curve to the dilution curve (for example by means of a Levenberg-Marquardt algorithm) and (ii) determining the model parameters from the model curve.
Alternatively, the model parameters can also be advantageously determined by means of the following partial steps: (i) determining a short-circuit peak that lies ahead of the dilution peak, (ii) determining a tangent to the dilution peak below the short-circuit peak, which encloses the greatest possible area with the dilution curve, and (iii) estimating the model parameters using curve parameters that can be determined from the location of the starting point of the dilution curve, the contact points of the tangent, the short-circuit peak, and the dilution peak.
Even though a central-vein catheter and an arterial catheter unit are provided according to a preferred embodiment, alternative embodiments of the invention can also be advantageous, in which the arterial signal is detected in non-invasive manner, for example by way of a tympanometric temperature measurement site or by means of optical methods, and/or the system disruption is triggered not in the central vein but rather in peripheral manner. In the last case mentioned, it merely needs to be known or possible to estimate with a sufficient approximation what additional delay as the result of the peripheral triggering must be taken into consideration.
Fundamentally, the disruption can take place by means of the introduction of heat, “introduction of cold” (injection of a cooled bolus), lithium chloride injection (LiCl), indocyanine green injection (ICG), or other indicators.
The disruption function can fundamentally have any desired progression (but one known with sufficient accuracy); for example, a pseudo-stochastic distribution is also possible.
Fundamentally, any variant of the invention described or indicated within the framework of the present application can be particularly advantageous, depending on the economic and technical conditions in an individual case. Unless something is stated to the contrary, and to the extent that this is fundamentally possible in technical terms, individual characteristics of the embodiments described are interchangeable or can be combined with one another.
In the following, examples of preferred embodiments of the present invention will be explained in greater detail, using the related drawings. In this connection, the drawings are to be understood as being purely schematic. They show:
The device shown in
An arterial catheter 12 (indicated in
The cold indicator moves from the injection site 10 to the measurement site 12, passing through the right atrium 2 and the left ventricle 3 of the heart 1, through the pulmonary circulation 5 by way of the pulmonary artery 4, with extravasal thermal volume (ETV, approximately equivalent to extravasal lung water volume EVLW) 15, through the left atrium 6, the left ventricle 7, and the aorta 8.
In place of the application of a cold indicator, other methods, which are actually known, for introducing a disruption in the circulation can also be advantageously used. For example, a heat pulse can be introduced by way of the central vein catheter 11, for which purpose the latter can be equipped with suitable heating agents. Furthermore, the injection of an optically detectable indicator is also possible, whereby the arterial catheter 12 can be equipped with a fiber-optic sensor for the concentration measurement, in order to determine the system response.
Using
Taking at least one of these possible short-circuit currents into account in calculating the cardiac output and/or other hemodynamic parameters is implemented in the program technology set-up of the evaluation unit 14, according to the invention.
A first ideally mixed volume V1 with a characteristic time τ1 is assumed for the right atrium RA, another ideally mixed volume V2 with a characteristic time τ2 is assumed for the right ventricle, a third ideally mixed volume V3 with a characteristic time τ3 and a delay element (“delay”) D3 is assumed for the totality of the pulmonary blood volume PBV and extravasal thermal volume ETV, and a fourth ideally mixed volume V4 with a characteristic time τ4 is assumed for the totality of the left atrium LA and left ventricle LV. The characteristic times τn are defined as the quotient of the corresponding volume Vn and the volume flow Qn through this volume.
Since a linear delay in the right and left half of the heart has an equivalent effect on the system response (“output”) y, corresponding effects are combined in the delay element (“delay”) D0. The delay element D0 can be taken into consideration by means of selecting a corrected starting time.
For the system response (“output”) y, the following applies:
y=I*D0*V1*(s·δ+(1−s)·V2*D3*V3)*V4
with convolution operator *, input function (“input”) or disruption function I, Dirac function δ, shunt ratio (ratio of shunt to cardiac output) s:=RLshunt/CO.
The measured dilution curve y, the typical progression of which, when a right-left shunt occurs, is sketched in
ys=y−yu
The shunt ratio s=RLshunt/CO corresponds to the quotient of the integral above the shunt curve ys and the integral above the measured curve y.
The disruption function I is considered to be a Dirac delta function with an ideally short injection time and indicator amount m, according to
I(m/CO)·δ(t)=co·δ(t)
The following applies for the time constant:
τ1=V1/CO
τ2=V2/((1−s)·CO)
τ3=V3/((1−s)·CO)
τ4=V4/CO
and
from this, the following is obtained:
In this, do and d3 designate the characteristic times that correspond to the delay elements D0 and D3, respectively. The initial concentration co can be determined by means of integration of the dilution curve:
co=∫ydt.
For the greatest volume V3, the characteristic time τ3 of the time constant DST (down slope time) of the exponential decay y∞exp(−t/DST) is equated with the dilution curve y after the dilution peak, according to
τ3=DST.
The mean transit time MTT that can be determined from the dilution curve according to
MTT=∫y·tdt/∫ydt
is equal to the sum of the characteristic times τ1, τ2, τ3, D3, τ4, so that
τ3=MTT−DST−τ1−τ2−d3.
For the right and left atrium as well as the right and left ventricle, simplifying constant volume conditions can be assumed, for example
τ1=0.6·τ2
and
τ4=1.3·τ2.
The remaining model parameters s, do and d3 can preferably be determined by means of a curve adaptation algorithm (for example the Levenberg-Marquardt algorithm).
By means of the model parameters determined according to the above equations, the evaluation unit 14 can calculate various hemodynamic parameters with lesser error deviations than is possible according to the state of the art:
Cardiac output:
CO=m/co
Pulmonary thermal volume:
PTV=V3=τ3·(1−s)·CO
Intrathoracic thermal volume:
ITTV=V1+V2+V3+V4=(τ1+τ4)·CO+(τ2+τ3)·(1−s)·CO
Global end-diastolic volume:
GEDV=V1+V2+V4=(τ1+τ4)·CO+τ2·(1−s)·CO
Intrathoracic blood volume:
ITBV=a·GEDV+b=a·((τ1+τ4)·CO+τ2·(1−s)·CO)+b
Extravasal lung water:
EVLW=ITTV−ITBV=(τ1+τ4)·CO+(τ2+τ3)·(1−s)·CO−a·((τ1+τ4)·CO+τ2·(1−s)·CO)+b
Cardiac function index:
CFI=CO/GEDV=1/(τ1+τ4+τ2·(1−s))
It is advantageous if the calculation operations are implemented in the program technology set-up of the evaluation unit 14 as follows. After estimating the starting point of the dilution curve y and the dilution peak with suitable criteria, which can be based on the state of the art, the mean transit time MTT and the decay time DST are calculated. The model function is adapted to the dilution curve determined by means of measurement technology by means of a suitable algorithm, with the least possible deviation. The cardiac output Co and the shunt ratio s are calculated with the model parameters from the adapted model function. Subsequently, the model volumes and other hemodynamic parameters can be calculated.
If the processor resources of the evaluation unit 14 are limited, it is advantageous that the calculation operations can also be implemented alternatively, essentially as follows, in the program technology set-up of the evaluation unit 14. After estimating the starting point of the dilution curve y and the dilution peak with suitable criteria, which can be based on the state of the art, the mean transit time MTT and the decay time DST are calculated. A shunt peak that lies ahead of the thermodilution peak is determined (see
Usually, an additional peak ahead of the dilution peak can always be considered to be a right-left shunt. In an extreme case, a right-left shunt peak can be as much as about 150% higher than the dilution peak.
A premature end of exponential decay, as sketched in
In order to take the left-right shunt into consideration, it is advantageous that fundamentally, similar calculation operations can be implemented in the evaluation unit 14 as for the determination of the right-left shunt. As illustrated in
A first ideally mixed volume V1 with a characteristic time τ1 is assumed for the right atrium RA, another ideally mixed volume V2 with a characteristic time τ2 is assumed for the right ventricle, a third ideally mixed volume V3 with a characteristic time τ3 and a delay element (“delay”) D3 is assumed for the totality of the pulmonary blood volume PBV and extravasal thermal volume ETV, and a fourth ideally mixed volume V4 with a characteristic time τ4 is assumed for the totality of the left atrium LA and left ventricle LV. The characteristic times τn are defined as the quotient of the corresponding volume Vn and the volume flow Qn through this volume.
Since a linear delay in the right and left half of the heart has an equivalent effect on the system response (“output”) y, corresponding effects are combined in the delay element (“delay”) D0. The delay element D0 can be taken into consideration by means of selecting a corrected starting time.
For the system response (“output”) y, the following applies:
y=(I*D0*V1+y·LRshunt·δ)*V2*D3*V3*V4
with convolution operator *, input function (“input”) or disruption function I, Dirac function δ and left-right shunt LRshunt.
In a first approximation, the disruption or input function (“input”) I can be considered to be a Dirac delta function δ, i.e. having a disappearing duration. Usually, however, an injection lasts about two seconds. In the shunt calculation, this can lead to a significant error. Alternatively to this, therefore, there is the possibility, according to the invention, of assuming a constant flow 1/p during the injection period p, for the disruption function I, and therefore of stating the disruption function I as the different of two Heaviside step functions according to
I=(σ(t)−σ(t−p))/p.
According to an advantageous further development of the invention, left-right shunt and right-left shunt can be taken into consideration simultaneously, with an expanded model and multi-dimensional curve adaptation, and furthermore, the re-circulation through the body circulation 9 can advantageously be taken into consideration. The related circuit schematic is shown in
A first ideally mixed volume V1 with a characteristic time τ1 is assumed for the right atrium RA, another ideally mixed volume V2 with a characteristic time τ2 is assumed for the right ventricle, a third ideally mixed volume V3 with a characteristic time τ3 and a delay element (“delay”) D3 with a characteristic time d3 is assumed for the totality of the pulmonary blood volume PBV and extravasal thermal volume ETV, and a fourth ideally mixed volume V4 with a characteristic time τ4 is assumed for the left atrium LA, and a fifth ideally mixed volume V5 with a characteristic time τ5 is assumed for the left ventricle LV. The characteristic times τn are again defined as the quotient of the corresponding volume Vn and the volume flow Qn through this volume.
Delay components in the right and left half of the heart are again summarized effects in the delay element (“delay”) D0, which can be taken into consideration by means of selecting a corrected starting time.
The left-right shunt, with shunt ratio sl, is connected in parallel, in the opposite flow direction, with the right ventricle RV, pulmonary blood volume PBV, left atrium LA, and left ventricle LV. The right-left shunt, with shunt ratio sr, is connected in parallel to the right ventricle and the pulmonary blood volume PBV. With regard to the re-circulation r, an ideally mixed volume V6 with a characteristic time τ6 for the systemic blood volume SBV and a delay element (“delay”) D3 with a characteristic time da are assumed.
For the system response y, the following applies:
y=(I*D0+r·y*D6*V6)*(V1+sl·y)*(srδ+(1−sr)·D3*V2*V3)*V4*V5
i.e.
y=(1=sr)·yu+sr·ysr+sl·ysl+r·yr
wherein the liquid elements of the blood that do not pass through any short circuit are described by a theoretical curve yu that is free of short circuits; the liquid elements that are attributable to the right-left shunt are described by a theoretical shunt curve ysr, the liquid elements that are attributable to the left-right shunt are described by a theoretical shunt curve ysl, and liquid elements that are attributable to the re-circulation are described by a theoretical curve ysr.
The mean transit time again corresponds to the sum of the time constants of the serial circuit:
MTT=τ1+τ2+d3+τ3+τ4+τ5
If all the volumes of the heart are equated to Vh, and only the first re-circulation pass is taken into consideration, the following is obtained:
Vh=V1=V2=V4=V5
yu=(1−sr)·I*D0*D3*Vh4*V3
ysr=sr·I*D0*Vh3
ysl≈sl·(yu+ysr)*D3*Vh3*V3
yr≈r·(yu+ysr)*D6*V6*D3*Vh4*V3
and finally
In general, as mentioned above, non-diffusible intravasal indicators, such as LiCl or ICG, can also be used. When non-diffusible intravasal indicators are used, cardiac output (CO) and global end-diastolic volume (GEDV) can be determined, but extravasal lung water (EVLW) cannot be determined. In this connection, the algorithms can fundamentally remain unchanged as compared with the algorithms described above, with the exception that then, the greatest intrathoracic dispersion volume corresponds to the intrathoracic blood volume ITBV (in the case of LiCl or ICG indicator) instead of the intrathoracic thermal volume ITTV (in the case of cold indicator).
Number | Date | Country | Kind |
---|---|---|---|
10 2005 007 592 | Feb 2005 | DE | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/EP2006/050006 | 1/3/2006 | WO | 00 | 11/14/2007 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2006/087245 | 8/24/2006 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
5135000 | Akselrod et al. | Aug 1992 | A |
5526817 | Pfeiffer et al. | Jun 1996 | A |
5595181 | Hubbard | Jan 1997 | A |
6470889 | Bae et al. | Oct 2002 | B1 |
6672172 | Tulkki et al. | Jan 2004 | B2 |
Number | Date | Country |
---|---|---|
1 236 435 | Sep 2002 | EP |
WO9321823 | Nov 1993 | WO |
WO 9748334 | Dec 1997 | WO |
WO9748334 | Dec 1997 | WO |
WO0130237 | May 2001 | WO |
Number | Date | Country | |
---|---|---|---|
20080146945 A1 | Jun 2008 | US |